Seres Therapeutics Inc [NASDAQ: MCRB] traded at a high on 10/31/23, posting a 5.52 gain after which it closed the day’ session at $1.53. The company report on October 30, 2023 at 5:30 PM that Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST.
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023. Management will host a conference call with investors to discuss the results and corporate updates at 8:00 a.m. ET.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The conference call may be accessed by calling 1-866-777-2509 (international callers dial 1-412-317-5413). Participants may pre-register for the conference call at https://dpregister.com/sreg/10184132/faf729b9c0.
The results of the trading session contributed to over 4365440 shares changing hands. Over the past one week, the price volatility of Seres Therapeutics Inc stands at 13.24% while the volatility over the past one month is 11.02%.
The market cap for MCRB stock reached $196.16 million, with 125.22 million shares outstanding and 96.47 million shares in the current float. Compared to the average trading volume of 2.47M shares, MCRB reached a trading volume of 4365440 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Seres Therapeutics Inc [MCRB]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $9.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 26, 2023.
The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.17, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 1.50. The Price to Book ratio for the last quarter was 8.66, with the Price to Cash per share for the same quarter was set at 1.79.
How has MCRB stock performed recently?
Seres Therapeutics Inc [MCRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.33. With this latest performance, MCRB shares dropped by -28.84% in over the last four-week period, additionally sinking by -67.24% over the last 6 months – not to mention a drop of -81.04% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 37.14, with the RSI for the last a single of trading hit 44.91, and the three-weeks RSI is set at 33.14 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 2.4253, while it was recorded at 1.4450 for the last single week of trading, and 4.5025 for the last 200 days.
Seres Therapeutics Inc [MCRB]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seres Therapeutics Inc [MCRB] shares currently have an operating margin of -3443.97 and a Gross Margin at -66.29. Seres Therapeutics Inc’s Net Margin is presently recorded at -3509.50.
Return on Total Capital for MCRB is now -138.66, given the latest momentum, and Return on Invested Capital for the company is -145.68. Return on Equity for this stock declined to -351.62, with Return on Assets sitting at -71.10. When it comes to the capital structure of this company, Seres Therapeutics Inc [MCRB] has a Total Debt to Total Equity ratio set at 1,507.84. Additionally, MCRB Total Debt to Total Capital is recorded at 93.78, with Total Debt to Total Assets ending up at 46.62. Long-Term Debt to Equity for the company is recorded at 1,470.21, with the Long-Term Debt to Total Capital now at 91.44.
Reflecting on the efficiency of the workforce at the company, Seres Therapeutics Inc [MCRB] managed to generate an average of -$580,411 per employee.Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.16 and a Current Ratio set at 3.23.
Insider trade positions for Seres Therapeutics Inc [MCRB]
The top three institutional holders of MCRB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in MCRB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in MCRB stock with ownership which is approximately 5.7994%.
